Bromantane

Short answer

Bromantane is a Russian adamantane actoprotector developed in the 1980s and approved there as Ladasten for neurasthenia and asthenia. Its distinctive mechanism is genomic: it raises tyrosine hydroxylase expression to increase dopamine synthesis rather than forcing release or blocking reuptake, which is why effects reportedly persist after discontinuation. The key trial was a 728-patient Russian multicenter study; independent Western replication is essentially absent, and it is sold elsewhere only as a research chemical.

Summary drafted from this entry’s sources; editorial review pending.

01Key questions

Does bromantane work for fatigue?

The main evidence is Russian: a 728-patient multicenter asthenia study reported 76% physician-rated improvement persisting a month after discontinuation, plus animal performance studies. Independent Western trials do not exist.

How does bromantane work?

It increases transcription of tyrosine hydroxylase and AADC, the dopamine-synthesis enzymes, via cAMP/PKC/PKA signaling, and suppresses GABA-transporter genes for an anxiolytic component. It is not a reuptake blocker or releaser like classic stimulants.

Is bromantane legal?

It is approved in Russia as Ladasten but not by the FDA or most Western regulators, and WADA has banned it since 1997. Elsewhere it circulates as an unregulated research chemical.

What would change this rating?

Independent non-Russian randomized trials plus modern human pharmacokinetic and long-term safety studies, the gaps the entry itself flags.

Synonyms: Bromantan, Bromontan, ADK-709, N-(4-Bromophenyl)adamantan-2-amine, Ladasten CAS: 87913-26-6 Formula: C₁₆H₂₀BrN (MW 306.25) Class: Adamantane derivative; Actoprotector (synthetic adaptogen); atypical CNS stimulant + anxiolytic

02Overview

Bromantane is a Russian-developed compound (1980s, Zakusov State Institute of Pharmacology, Moscow) classified as an actoprotector — a synthetic adaptogen designed to enhance physical and mental performance under extreme conditions (hypoxia, heat, fatigue, emotional stress) without increasing oxygen consumption or heat production. It was used in Soviet/Russian military, space, and sports medicine. Approved in Russia (as Ladasten) for neurasthenia/asthenia (persistent fatigue with anxiety). Not approved by FDA or most Western regulators; sold elsewhere as a research chemical. Banned by WADA as a stimulant/masking agent since 1997 (detected in 1996 Atlanta Olympics Russian athletes).

It stands out from typical stimulants (amphetamine, methylphenidate, cocaine) due to its genomic mechanism that upregulates dopamine biosynthesis enzymes rather than blocking reuptake or forcing release. Benefits often persist weeks after discontinuation. Low side-effect profile in clinical use; no observed tolerance or dependence in studies.

03History & Development

Developed in the 1980s as part of Soviet research into actoprotectors (pioneered by Prof. Vladimir Vinogradov’s team at the Military Medical Academy).
Related to earlier actoprotector bemitil (used by cosmonauts and athletes).
Soviet military use: Shortened recovery after physical exertion; tested in Afghanistan for marching fatigue and heat stress; used across Army, Air Forces, Navy for endurance, hypoxia resistance.
Post-USSR: Continued in sports medicine; 1996 Olympic doping incident → WADA ban.
Russian approval: ~1997–2009 as Ladasten for neurasthenia (F48.0 ICD-10). Large-scale trials supported safety/efficacy.
Immunomodulatory and anti-inflammatory properties noted in some studies.

Lost Soviet Medical Knowledge angle: Exemplifies pragmatic Soviet pharmacology focused on performance under duress with minimal exhaustion — contrasts with Western stimulant paradigms that often lead to crash and dependence.

04Chemistry & Structure

Adamantane “cage” linked to 4-bromoaniline. Structurally related to amantadine and memantine but pharmacologically distinct. Poor water solubility; oral bioavailability ~42%.

05Mechanism of Action (Deep Dive)

Primary effects stem from indirect genomic actions activating intracellular signaling (cAMP-, Ca²⁺-, phospholipid-dependent protein kinases, especially PKC and PKA) → increased transcription of key enzymes.

Dopamine Synthesis Upregulation (Core MOA)

Rapid, pronounced, long-lasting upregulation of tyrosine hydroxylase (TH) and aromatic L-amino acid decarboxylase (AADC/DDC) expression in hypothalamus, striatum, VTA, nucleus accumbens, etc.
A single dose raised tyrosine hydroxylase expression 2–2.5× in rat hypothalamus within 1.5–2 hours.
Leads to increased de novo dopamine biosynthesis and release (correlates with enzyme upregulation).
Not clinically relevant reuptake inhibition (requires very high in vitro concentrations, 50–500 μM). Differs sharply from amphetamines (release) or methylphenidate (DAT blockade).
Result: Steady dopaminergic enhancement without hyperstimulation, peripheral sympathomimetic overload, or rapid depletion.

GABAergic Modulation (Anxiolytic Component)

Suppresses expression of GABA transporter genes (e.g., GAT3) → enhanced GABAergic transmission and availability in synapses.
Contributes to calm, non-sedating anxiolytic effects.

Neurotrophins & Neuroprotection

Increases expression of BDNF and NGF (nerve growth factor) in striatum, hypothalamus, hippocampus (rat studies, 50 mg/kg single dose).
Activates mitogen-activated protein kinase cascade (ERK1/ERK2 and pERK).
Potential downstream effects: neuronal survival, plasticity, reduced inflammatory cytokines (IL-6, IL-17, IL-4 in models).
May contribute to lasting benefits post-discontinuation and possible anti-depressant-like or neuroprotective actions.

Other

Possible mild serotonergic effects (increased 5-HT and 5-HIAA in some regions).
σ1 receptor agonism hypothesized (shared with amantadine/memantine) but not confirmed as primary for bromantane.
Anti-hypoxic and membrane-protective effects observed in physical performance studies.

Key Distinction from Typical Stimulants (literature quotes): - No addictive potential, withdrawal, or functional exhaustion. - No redundant sympathoadrenergic activation. - Performance enhancement without hyperstimulation.

06Pharmacokinetics

Onset: 1.5–2 hours (oral)
Duration: 8–12 hours (oral)
Half-life: ~11.21 hours (humans); ~7 hours (rats, brain)
Bioavailability: ~42%
Metabolism: Cytochrome P450 (CYP) induction reported — potential for interactions with CYP-metabolized drugs (e.g., benzodiazepines, SSRIs, oral contraceptives). Metabolites may have anticholinergic profile at lower doses.
Excretion: Limited human data; animal studies show effects lasting ≥24h in some performance metrics.
Routes: Primarily oral (tablets/capsules/powder). Nasal/sublingual discussed anecdotally but lack clinical validation.

07Clinical Evidence

Landmark Trial (Asthenia/Neurasthenia)

Multi-center Russian study: 728 patients with asthenia.
Results: 76% physician-rated improvement (CGI-S 76%, CGI-I 90.8%). Benefits on fatigue, mood, motivation, and sleep persisted 1 month after discontinuation.
Side effects: 3% (none serious); 0.8% discontinuation.
Also normalized sleep-wake cycle.

Other Russian Studies

Improved attention, operational performance, sensomotor capabilities.
Immunomodulatory effects (T-cell subsets in social defeat depression model).
Physical work capacity: Superior to phenamine (amphetamine) in swimming/treadmill tests (mice/rats); 0.5–50 mg/kg; effects ≥24h; protects mitochondria in heart/skeletal muscle.
Heat protection, hypoxia resistance, cardiovascular effects (increased stroke/minute volume at reduced HR and peripheral resistance).
Toxicology (single dose, rats): Stimulant at 30–300 mg/kg; suppression at higher doses; LD50 very high (~1,750–8,100 mg/kg range in reports).

Limitations: Most data from Russian sources (1990s–2010s); limited independent Western replication. Strong internal consistency across studies.

08Effects & Benefits

Fatigue/Asthenia: Primary approved use; robust clinical support.
Performance under stress: Physical endurance, resistance to heat/hypoxia/fatigue without burnout.
Cognitive/Motivational: Subtle stimulation, increased motivation, focus with reduced errors (vs. amphetamines which increase speed but also errors). “Better-rested version of yourself.”
Anxiolytic: Calm energy without sedation or dependence (distinct from benzos or phenibut).
Mood/Sleep: Possible antidepressant-like (cytokine reduction, neurotrophins); normalizes sleep-wake.
Other (preclinical): Increased sexual receptivity (dopaminergic); potential prolactin suppression; lasting dopaminergic sensitization (up to 1–2 months in some animal data).

Onset of subjective effects: Often gradual; anxiolytic may appear faster than full motivational effects (days 1–7).

09Practical Context

Timing: Morning only (insomnia risk if dosed later; effects 6–12h).
Stacking notes (theoretical): Pair with L-tyrosine (substrate for TH) 500–1000 mg. Potential synergy with other adaptogens or nootropics, but limited data.
Forms: Powder, capsules. Research chemical quality varies — demand batch-specific COAs.

Upper limits: Anecdotal up to 200 mg; diminishing returns and higher side-effect risk.

10Safety, Side Effects & Toxicology

Favorable profile at therapeutic doses: - Common (∼3% in trial): Mild insomnia (timing-related), headache, irritability. - Higher doses: Tension, restlessness, “wired but tired.” - Absent: Tolerance, dependence, withdrawal, addiction potential, significant cardiovascular stimulation, hyperstimulation. - LD50: Extremely high (mice ~8,100 mg/kg reported; rats ~1,750+ mg/kg). - hERG: Predictive models sometimes flag; contradicted by actual cardiovascular data (increased output, reduced resistance). Not a clinical concern per available evidence. - CYP induction: Clinically relevant — may reduce levels of co-administered CYP substrates. Avoid with MAOIs. - Other: High doses in animals caused regurgitation, diarrhea, polyuria, mild hypothermia. No pro-hypoxic activity.

Contraindications/Interactions: Limited data; caution with CYP drugs, stimulants, or in cardiovascular patients (though some data support use in somatogenic asthenia with CV pathology).

Special populations: Not studied in pregnancy, pediatrics, etc. Research chemical status outside Russia means quality/safety responsibility on user.

11Comparisons

Vs. Bemitil (another actoprotector): Bromantane more dopaminergic/psychostimulant; bemitil more metabolic/anti-hypoxic.
Vs. Amantadine/Memantine: Shared family; bromantane stronger on dopamine synthesis upregulation.
Vs. Typical stimulants: No crash, tolerance, or peripheral overload; genomic vs. acute synaptic action.
Vs. Modafinil/Eugeroics: Different profile (anxiolytic + performance under duress vs. wakefulness promotion).

12Anecdotal Reports (Nootropics Communities)

Common themes: Subtle but effective motivation/energy for work/gym; reduced alcohol desire; variable emotional effects (some report mood swings); insomnia if dosed late; “clean” feel compared to other stimulants. Individual variation high; many praise lack of tolerance.

13Sourcing & Research Notes

Available as research chemical (powder/capsules/liquid). Prioritize vendors with third-party COAs. Not for human consumption in most jurisdictions. Quality control critical due to research status.

14Where to get it

No links for this entry

Bromantane is sold mainly through gray-market vendors whose products are not independently tested. We don't link to sellers of compounds like this, affiliate or otherwise. How we make money